Oravax Medical, Oramed subsidiary, signed an agreement with Vietnam’s Tan Thanh Holdings Investment Joint Stock Company to prepurchase ten million doses of Oravax’s oral COVID-19 vaccine, which is currently in development.
Tan Thanh Holdings will have the exclusive right to sell Oravax’s in-development oral vaccine throughout the Association of Southeast Asian Nations (ASEAN), which includes Vietnam, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, and Thailand.
“This prepurchase of our oral COVID-19 vaccine in development represents a significant milestone for Oravax Medical and another step forward in the implementation of our long-term strategy,” said Nadav Kidron, CEO and Chairman of Oramed and Oravax.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Additionally, Tan Thanh Holdings has been granted authority by the Vietnamese Ministry of Health to perform advanced-stage clinical trials on the vaccine in order to expedite its regulatory approval.
“With the rapid increase in positive cases of the Omicron variation, there is an urgent need for a universal oral vaccine that protects against existing and future variants,” Kidron noted. “The development of an oral COVID-19 vaccine would significantly improve vaccination logistics and costs.
“Tan Thanh Holdings is a great partner for bringing our vaccine to Vietnam and the ASEAN region,” he added.
Oravax created a revolutionary oral virus-like particle COVID-19 vaccination using Oramed’s “POD” oral delivery technology. This technology enables the oral administration of a variety of protein-based medicines that would otherwise be administered via injection. The vaccine was developed in conjunction with Premas, an Indian pharmaceutical business.
Oravax’s vaccine candidate targets three unique coronavirus structural proteins, as opposed to the single spike protein targeted by the current Moderna and Pfizer vaccines, Kidron explained.
As a result, he stated, “this vaccine should be significantly more resistant to COVID-19 variants.” Even if the virus penetrates one line, there is a second, and if the virus penetrates the second, there is a third.”
Earlier this month, the business began a Phase I clinical trial in South Africa.
